Nuvation Bio Inc. (NUVB) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to the New Vision Bios second quarter 2025 financial results and corporate update call. Today's call is being recorded and a replay will be available. All participants are currently in a listen-only mode. A brief question and answer session will follow the prepared remarks. Now, I would like to turn the call over to Gerald DeVito, Executive Director of Corporate Development and Investor Relations at NuvationBio. Please go ahead. Thank you, and good morning, everyone. Welcome to the NuvationBio second quarter 2025 earnings conference call. Earlier today, we released financial results for the quarter ending June 30, 2025, and provided a business update. The press release is available on the investor section of our website at nuvationbio.com. A recording of this conference call can also be found on the investor section of our website following its completion. I'd like to remind you that today's call includes forward-looking statements about Iptrosi's launch, our pipeline progress, and our cash runway. Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 10-K and our quarterly reports on Form 10-Q that are filed with the U.S. Securities and Exchange Commission. Joining me on today's call to discuss our quarterly results are our founder, president, and chief executive officer, Dr. David Hung, and our chief financial officer, Philippe Sauvage. David will provide an overview of the Obtruse commercial launch and additional pipeline updates, and Philippe will discuss our financial and operating updates for the quarter. David will then conc...